Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 988 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (treatment C) Clear all
Terminated Not applicable Interventional Results available

Study of Mitomycin-C Application in Laryngotracheal Stenosis

NCT01523275
View directory record Official record
Conditions
Laryngeal Stenosis, Subglottic Stenosis, Tracheal Stenosis
Interventions
Mitomycin -C, Saline application
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Early Phase 1 Interventional Results available

Treatment of HFpEF With Nitrate Supplement

NCT03289481
View directory record Official record
Conditions
Heart Failure With Normal Ejection Fraction
Interventions
Active lozenge, Placebo
Dietary Supplement · Drug
Lead sponsor
MaineHealth
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rockport, Maine
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain

NCT01216163
View directory record Official record
Conditions
Pain
Interventions
Novel Ibuprofen, Acetaminophen, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 40 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers

NCT00467493
View directory record Official record
Conditions
Menstruation Disorders
Interventions
Anastrozole
Drug
Lead sponsor
Meditrina Pharmaceuticals
Industry
Eligibility
25 Years to 45 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Kalamazoo, Michigan • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 3, 2009 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 18, 2026, 10:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Study Evaluating the Impact of Regular FODMAP-targeting Digestive Enzyme Blend Use on Gastrointestinal Symptoms in Individuals With Self-Reported Bloating

NCT07591584
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), Bloating, Abdominal Pain, Gut Health
Interventions
FODMAP-targeting digestive enzyme blend, Placebo
Dietary Supplement · Other
Lead sponsor
Kiwi Health Inc
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

NCT03227471
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
IVA, TEZ/IVA, VX-445, Matched Placebo, TEZ, VX-561
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Madera, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 18, 2026, 10:16 AM EDT
Terminated Phase 2 Interventional

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

NCT02043587
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions
DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
4
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 18, 2026, 10:16 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

NCT04660344
View directory record Official record
Conditions
Muscle-invasive Bladder Cancer
Interventions
Atezolizumab, Placebo, Signatera
Drug · Other · Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Rockledge, Florida • Cleveland, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 18, 2026, 10:16 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

NCT05153499
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
CP101, Placebo
Biological · Other
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
61
States / cities
Phoenix, Arizona • Mission Hills, California • Oakland, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 2 Interventional Results available

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

NCT02203552
View directory record Official record
Conditions
Anxiety Disorder, Depression, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
minocycline hydrochloride, placebo, laboratory biomarker analysis, Questionnaire administration
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional

Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile

NCT03827447
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Vancomycin Oral Capsule, Placebo Oral Capsule
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Results available

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)

NCT01395914
View directory record Official record
Conditions
Cachexia, Non-Small Cell Lung Cancer
Interventions
Anamorelin HCl, Placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years and older
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
19
States / cities
Corona, California • Fountain Valley, California • Fullerton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 2 Interventional

Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder

NCT00026585
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Tamoxifen
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 2 Interventional

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

NCT01482390
View directory record Official record
Conditions
Hepatitis C
Interventions
Ribavirin, Mericitabine, Peginterferon Alfa-2a, Placebo, Telaprevir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo

NCT01616485
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
TA-1790, Sildenafil citrate, Placebo, Nitrostat
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

NCT01591668
View directory record Official record
Conditions
Hepatitis C
Interventions
Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

NCT05736874
View directory record Official record
Conditions
Covid19
Interventions
Fluticasone, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 18, 2026, 10:16 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

NCT07837973
View directory record Official record
Conditions
Overweight , Obesity, Adults
Interventions
ALV-100, Placebo
Drug
Lead sponsor
Alveus Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Placebo-Controlled Study Assessing the Use of a Novel Exfoliative Serum With A Chemical Peel to Improve Photodamage in Adults

NCT05908825
View directory record Official record
Conditions
Photodamaged Skin
Interventions
Vitamin C with AHA Exfoliative Serum, Placebo serum
Drug
Lead sponsor
Austin Institute for Clinical Research
Network
Eligibility
30 Years to 65 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pflugerville, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 3 Interventional

Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee

NCT03291470
View directory record Official record
Conditions
Degenerative Osteoarthritis
Interventions
TG-C, Placebo Control
Biological
Lead sponsor
Kolon TissueGene, Inc.
Industry
Eligibility
40 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
27
States / cities
Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 18, 2026, 10:16 AM EDT
Recruiting Phase 3 Interventional

A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C

NCT05163288
View directory record Official record
Conditions
Niemann-Pick Disease, Type C
Interventions
N-Acetyl-L-Leucine, Placebo
Drug · Other
Lead sponsor
IntraBio Inc
Industry
Eligibility
4 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCT03565068
View directory record Official record
Conditions
Schizophrenia
Interventions
MK-8189, Placebo, Background AAP Therapy
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 18, 2026, 10:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

NCT02641561
View directory record Official record
Conditions
Post-ERCP Acute Pancreatitis
Interventions
Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 18, 2026, 10:16 AM EDT